C2 PHARMA Completes Multiple Regulatory Filings, Expands Portfolio Posted on 23. February 202117. March 2021 by c2p-editor
Andrew Badrot, C2 PHARMA CEO, speaks on working to mitigate risks for future crises like the COVID-19 pandemic Posted on 18. December 202023. February 2021 by c2p-editor
Interview with Andrew Badrot, C2 PHARMA CEO, a “Lëtzebuerger Merkur” Featured Story Posted on 19. November 202023. February 2021 by c2p-editor
C2 PHARMA Finalist in Excellence in Pharma: Sustainability, the CPhI Pharma Awards 2020 Posted on 23. September 202028. September 2020 by c2p-editor
The Impact of Covid-19 on the Pharmaceutical Industry Posted on 31. August 20201. September 2020 by c2p-editor
Connecting industry across the globe, a Chemicals Knowledge featured story Posted on 27. August 202023. February 2021 by c2p-editor
Andrew Badrot, CEO of C2 PHARMA, speaks on how the pharma industry has responded to the COVID-19 pandemic, a Pharma’s Almanac Q2 issue Posted on 1. July 202023. February 2021 by c2p-editor
Lessons from a modern-day pandemic: redesigning the pharmaceutical supply chain, a Manufacturing Chemist featured story Posted on 15. May 20207. July 2020 by c2p-editor
COVID-19/Coronavirus is reshaping the pharmaceutical supply chain Posted on 27. April 20207. July 2020 by c2p-editor
C2 PHARMA Opens Government and Research Access to Safety Stock of DIGOXIN API for Use in Potential COVID-19/Coronavirus Combination Treatment Posted on 26. March 202023. February 2021 by c2p-editor
Andrew Badrot, CEO of C2 PHARMA, weighs in on the future trends of mergers and acquisitions in the life sciences industry Posted on 19. March 202023. February 2021 by c2p-editor
C2 PHARMA Expands Advisory Board to Support Growth Objectives Posted on 3. March 202023. February 2021 by c2p-editor
Fairness in the pharma supply chain key to success in today’s business climate Posted on 9. January 20202. October 2020 by c2p-editor
Andrew Badrot, CEO of C2 PHARMA, speaks on developing technologies that will have the greatest impact on the biopharma industry in 2020 and beyond, a Pharma’s Almanac Q4 issue Posted on 6. December 201923. February 2021 by c2p-editor
C2 PHARMA Continues to Expand API Portfolio with Digoxin Micronized Grade, Homatropine Hydrobromide and Multiple Products Under Tech Transfer and Development Posted on 4. November 201923. February 2021 by c2p-editor
C2 PHARMA leverages virtual manufacturing to build secure supply chains, a Chemicals Knowledge featured story Posted on 2. September 201923. February 2021 by c2p-editor
Building resilient supply chains for niche APIs How C² PHARMA overcame the Digoxin challenge Posted on 6. June 20197. June 2019 by c2p-editor
C2 PHARMA Acquires Digoxin API Portfolio from Nobilus Ent Posted on 20. March 201923. February 2021 by c2p-editor